Piper Sandler Downgrades Capricor Therapeutics to Neutral, Lowers Price Target to $2
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsDowngradesPrice Target
Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.
Piper Sandler analyst Edward Tenthoff downgrades Capricor Therapeutics (NASDAQ:CAPR) from Overweight to Neutral and lowers the price target from $58 to $2.